Skip to main content
OpenTrials
Completed

NCT Number: NCT05645731

Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study

Lung cancer screening of active or former heavy smokers with yearly low-dose CT allows for earlier diagnosis and better lung cancer survival. Risk of developing lung cancer is higher among family members and close contacts of lung cancer patients, because of shared genetics, environment and life habits like smoking. The investigators want to engage lung cancer patients to refer their family members and close contacts for lung cancer screening, and evaluate if this referred population have higher risk of lung cancer than the population referred by their family doctors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Behavior Health Behavior Lung Cancer Screening Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Patient Acceptance of Health Care Patient Empowerment Patient Participation Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MUHC

Montreal, Quebec, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Lung cancer patients:

Inclusion criteria

  • > 18 years old
  • Current or former lung cancer patient

Exclusion criteria

none

Referred participants Inclusion criteria: >18 years old Exclusion criteria: Personal history of lung cancer.

Treatment and study plan

Primary outcomes

  1. Mean number of referrals for lung cancer screening per participants

    Time frame: 2 weeks post inclusion

    Mean number of referrals for lung cancer screening per participants: lung cancer participants will refer contacts directly on the REDCap questionnaire at enrollment. They will be contacted a second time 2 weeks after enrollment and asked if they referred additional people in their entourage for lung cancer screening.

  2. Mean PLCOm2012 risk prediction model score among referred participants

    Time frame: baseline

    Mean risk of developing lung cancer in the next 6 years using the validated PLCOm2012 risk prediction model in smokers or ex-smokers referred participants that are 55 to 74 years old.

Secondary outcomes

  1. Number of visitors on our website for referred participants

    Time frame: 6 months

    Quantification of people who visited the website for close contacts of lung cancer patients: Number of unique access to website based on google analytics data.

  2. Number of people who started to fill the enrollment form for referred participants.

    Time frame: 6 months

    Number of people who started to fill the enrollment form for referred participants.

  3. Number of referred participants who enrolled in the study.

    Time frame: 6 months

    Number of referred participants who enrolled in the study.

  4. PLCO score as a binary outcome (above or below 2%) among referred participants

    Time frame: baseline

  5. Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient

    Time frame: 18 months

    Proportion of LCS eligible participants who will complete lung cancer screening within 18 months of referral by a lung cancer patient

  6. Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk.

    Time frame: baseline

    Proportion of individuals who would theoretically demonstrate interest in genetic testing to assess for lung cancer risk.

  7. Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers

    Time frame: baseline

    Proportion of individuals who demonstrate interest in referral to a smoking cessation program among referred participants that are current smokers

  8. Anxiety regarding lung cancer for referred participants

    Time frame: baseline

    GAD7

  9. Anxiety regarding lung cancer for referred participants

    Time frame: 1 month

    GAD7

Sponsors and collaborators

Lead sponsor

Nicole Ezer, MD, FRCPC, MPH

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Dec 9, 2022
Registry last updated
Aug 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.